Advances in Therapy

, Volume 28, Issue 2, pp 126–133

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib


DOI: 10.1007/s12325-010-0096-4

Cite this article as:
Heigener, D.F. & Reck, M. Adv Therapy (2011) 28: 126. doi:10.1007/s12325-010-0096-4


Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of “acquired resistance” have been discovered and treatments for this specific entity are on the horizon.


EGFR erlotinib gefitinib mutation non-small cell lung cancer 

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  1. 1.Hospital GrosshansdorfGrosshansdrof, HamburgGermany

Personalised recommendations